on Bb Biotech (isin : CH0038389992)
BB Biotech AG Announces Strong First Quarter Results in 2024 Interim Report
BB Biotech AG, the investment company specialized in biotechnology, revealed a significant reversal in its financial performance for the first quarter of 2024. The newly released interim report indicates a net profit of CHF 260 million for the period ending March 31, 2024. This contrasts starkly with the loss of CHF 254 million reported in the same period last year.
The report highlights that these results mirror the share price progression of its portfolio companies, demonstrating a successful quarter for the firm’s investment strategy. Further details of the report can be found on the company's website and its dedicated report portal.
R. P.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Bb Biotech news